NCHR Testimony on Fablyn

September 8, 2008. Osteoporosis is a serious disease. Fortunately, there are numerous treatments available, and those options should help the FDA determine whether the risks of this drug, Fablyn, outweigh the benefits.

Read More »

NCHR Statement on FDA Breast Implant Decision

July 28, 2005. The Food and Drug Administration (FDA) has issued an “approvable letter” to Mentor regarding their silicone gel breast implants. This does not mean that these implants have been approved, but it is a warning sign that corporate pressure on the FDA has once again put women’s health at risk.

Read More »

NCHR Testimony at FDA on Hylaform

November 21, 2003. One concern about Hylaform is the lack of data for African Americans and Asian Americans. Only three of the patients are African American and only five are Asian American.

Read More »